2026年9月17日，亚盛医药集团(06855)发布自愿公告称，其受托人已于同日通过联交所场内累计购入公司股份共计50,000股，用于满足2022年限制性股份单位计划的归属需求。
本次购股的关键数据如下： 1. 购股数量：50,000股，占公告日已发行股份总数约0.01%。 2. 总代价：1,508,138港元，折合约150.81万港元（不含相关费用及税项）。 3. 每股平均代价：约30.16港元（不含相关费用及税项）。
截至上述交易完成后，受托人已就2022年限制性股份单位计划目的合计在场内购入2,665,000股公司股份。
根据公告，受托人持有的相关股份将按照2022年限制性股份单位计划规则及信托契据条款进行管理，期间不享有表决权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.